引用本文:谢 莹,查 艳,林 鑫,袁 静,李 倩,曾 雯.曲美他嗪联合左卡尼汀治疗尿毒症心肌病的疗效观察[J].中国临床新医学,2019,12(12):1283-1286.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 140次   下载 155 本文二维码信息
码上扫一扫!
分享到: 微信 更多
曲美他嗪联合左卡尼汀治疗尿毒症心肌病的疗效观察
谢 莹,查 艳,林 鑫,袁 静,李 倩,曾 雯
550002 贵阳,贵州省人民医院肾内科
摘要:
[摘要] 目的 探讨曲美他嗪联合左卡尼汀治疗尿毒症心肌病的临床效果。方法 选择2016-01~2017-12该院收治的58例尿毒症心肌病患者,随机分为对照组(29例)和观察组(29例)。对照组给予左卡尼汀及常规综合治疗,观察组给予曲美他嗪联合左卡尼汀治疗及常规综合治疗,两组均连续治疗3个月,比较治疗前后两组患者心功能变化。结果 治疗后,两组患者脑钠肽(BNP)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)水平均低于治疗前,且观察组水平低于对照组,差异有统计学意义(P<0.05);左室射血分数(LVEF)水平高于治疗前,且观察组水平高于对照组,差异有统计学意义(P<0.05)。结论 曲美他嗪联合左卡尼汀较单用左卡尼汀治疗尿毒症心肌病效果好,可减少心肌缺血,提高心肌收缩力,改善患者的心功能状态,应用方便,安全性高,副作用小,值得临床推广。
关键词:  曲美他嗪  左卡尼汀  尿毒症心肌病  血液透析
DOI:10.3969/j.issn.1674-3806.2019.12.07
分类号:R 453.9
基金项目:贵州省高层次创新人才项目(编号:黔科合平台人才[2018]5636);贵州省科技计划项目(编号:黔科合LH字[2016]7170);贵州省人民医院青年基金项目(编号:GZSYQN[2016]11号)
Clinical effects of trimetazidine combined with L-carnitine on treatment of uremic cardiomyopathy
XIE Ying, ZHA Yan, LIN Xin, et al.
Department of Nephrology, the People′s Hospital of Guizhou Province, Guiyang 550002, China
Abstract:
[Abstract] Objective To investigate the clinical effects of trimetazidine combined with L-carnitine on treatment of uremic cardiomyopathy. Methods Fifty-eight patients with uremic cardiomyopathy were selected in our hospital during January 2016 and December 2017 and were randomly divided into control group and observation group. The control group(n=29) was treated with L-carnitine and routine comprehensive treatment, and the observation group(n=29) was treated with trimetazidine combined with L-carnitine and routine comprehensive treatment. Both of the two groups were treated continuously for 3 months. The changes of heart function were compared between the two groups before and after treatment. Results After treatment, the levels of brain natriuretic peptide(BNP), creatine kinase(CK), creatine kinase isoenzyme(CK-MB) and lactate dehydrogenase(LDH) in the two groups were significantly lower than those before treatment, and the decreased effects of the observation group were more significant than those of the control group(P<0.05). After treatment, the levels of left ventrcular ejection fraction(LVEF) in the two groups were significantly higher than those before treatment, and the increased effect of the observation group was more significant than that of the control group(P<0.05). Conclusion Trimetazidine combined with L-carnitine is more effective than L-carnitine alone in treatment of uremic cardiomyopathy. Trimetazidine combined with L-carnitine therapy can reduce myocardial ischemia, improve myocardial contractility and cardiac function of the patients. This combination therapy is convenient, safe and has few side effects, which is worthy of clinical application.
Key words:  Trimetazidine  L-carnitine  Uremic cardiomyopathy  Hematodialysis